Sarina Pasricha1, William J Bulsiewicz1, Kelly E Hathorn1, Srinadh Komanduri2, V Raman Muthusamy3, Richard I Rothstein4, Herbert C Wolfsen5, Charles J Lightdale6, Bergein F Overholt7, Daniel S Camara8, Evan S Dellon1, William D Lyday9, Atilla Ertan10, Gary W Chmielewski11, Nicholas J Shaheen12. 1. Center for Esophageal Diseases and Swallowing, Division of Gastroenterology and Hepatology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina. 2. Division of Gastroenterology and Hepatology, Northwestern University School of Medicine, Chicago, Illinois. 3. Division of Gastroenterology and Hepatology, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, California. 4. Division of Gastroenterology and Hepatology, Dartmouth University School of Medicine, Hanover, New Hampshire. 5. Division of Gastroenterology and Hepatology, Mayo Clinic Florida, Jacksonville, Florida. 6. Division of Gastroenterology and Hepatology, Columbia University School of Medicine, New York, New York. 7. Gastrointestinal Associates, Knoxville, Tennessee. 8. Digestive Health Physicians, Cheektowaga, New York. 9. Atlanta Gastroenterology Associates, Atlanta, Georgia. 10. Division of Gastroenterolgy and Hepatology, University of Texas School of Medicine, Houston, Texas. 11. Division of Thoracic Surgery, Rush Medical College, Chicago, Illinois. 12. Center for Esophageal Diseases and Swallowing, Division of Gastroenterology and Hepatology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina. Electronic address: nicholas_shaheen@med.unc.edu.
Abstract
BACKGROUND & AIMS: After radiofrequency ablation (RFA), patients may experience recurrence of Barrett's esophagus (BE) after complete eradication of intestinal metaplasia (CEIM). Rates and predictors of recurrence after successful eradication have been poorly described. METHODS: We used the US RFA Registry, a nationwide registry of BE patients receiving RFA, to determine rates and factors that predicted recurrence of intestinal metaplasia (IM). We assessed recurrence by Kaplan-Meier analysis for the overall cohort and by worst pretreatment histology. Characteristics associated with recurrence were included in a logistic regression model to identify independent predictors. RESULTS: Among 5521 patients, 3728 had biopsies 12 months or more after initiation of RFA. Of these, 3169 (85%) achieved CEIM, and 1634 (30%) met inclusion criteria. The average follow-up period was 2.4 years after CEIM. IM recurred in 334 (20%) and was nondysplastic or indefinite for dysplasia in 86% (287 of 334); the average length of recurrent BE was 0.6 cm. In Kaplan-Meier analysis, more advanced pretreatment histology was associated with an increased yearly recurrence rate. Compared with patients without recurrence, patients with recurrence were more likely, based on bivariate analysis, to be older, have longer BE segments, be non-Caucasian, have dysplastic BE before treatment, and require more treatment sessions. In multivariate analysis, the likelihood for recurrence was associated with increasing age and BE length, and non-Caucasian race. CONCLUSIONS: BE recurred in 20% of patients followed up for an average of 2.4 years after CEIM. Most recurrences were short segments and were nondysplastic or indefinite for dysplasia. Older age, non-Caucasian race, and increasing length of BE length were all risk factors. These risk factors should be considered when planning post-RFA surveillance intervals.
BACKGROUND & AIMS: After radiofrequency ablation (RFA), patients may experience recurrence of Barrett's esophagus (BE) after complete eradication of intestinal metaplasia (CEIM). Rates and predictors of recurrence after successful eradication have been poorly described. METHODS: We used the US RFA Registry, a nationwide registry of BE patients receiving RFA, to determine rates and factors that predicted recurrence of intestinal metaplasia (IM). We assessed recurrence by Kaplan-Meier analysis for the overall cohort and by worst pretreatment histology. Characteristics associated with recurrence were included in a logistic regression model to identify independent predictors. RESULTS: Among 5521 patients, 3728 had biopsies 12 months or more after initiation of RFA. Of these, 3169 (85%) achieved CEIM, and 1634 (30%) met inclusion criteria. The average follow-up period was 2.4 years after CEIM. IM recurred in 334 (20%) and was nondysplastic or indefinite for dysplasia in 86% (287 of 334); the average length of recurrent BE was 0.6 cm. In Kaplan-Meier analysis, more advanced pretreatment histology was associated with an increased yearly recurrence rate. Compared with patients without recurrence, patients with recurrence were more likely, based on bivariate analysis, to be older, have longer BE segments, be non-Caucasian, have dysplastic BE before treatment, and require more treatment sessions. In multivariate analysis, the likelihood for recurrence was associated with increasing age and BE length, and non-Caucasian race. CONCLUSIONS: BE recurred in 20% of patients followed up for an average of 2.4 years after CEIM. Most recurrences were short segments and were nondysplastic or indefinite for dysplasia. Older age, non-Caucasian race, and increasing length of BE length were all risk factors. These risk factors should be considered when planning post-RFA surveillance intervals.
Authors: Jukka Ronkainen; Pertti Aro; Tom Storskrubb; Sven-Erik Johansson; Tore Lind; Elisabeth Bolling-Sternevald; Michael Vieth; Manfred Stolte; Nicholas J Talley; Lars Agréus Journal: Gastroenterology Date: 2005-12 Impact factor: 22.682
Authors: B J Reid; R C Haggitt; C E Rubin; G Roth; C M Surawicz; G Van Belle; K Lewin; W M Weinstein; D A Antonioli; H Goldman Journal: Hum Pathol Date: 1988-02 Impact factor: 3.466
Authors: E Montgomery; M P Bronner; J R Goldblum; J K Greenson; M M Haber; J Hart; L W Lamps; G Y Lauwers; A J Lazenby; D N Lewin; M E Robert; A Y Toledano; Y Shyr; K Washington Journal: Hum Pathol Date: 2001-04 Impact factor: 3.466
Authors: Virender K Sharma; H Jae Kim; Ananya Das; Christopher D Wells; Cuong C Nguyen; David E Fleischer Journal: Am J Gastroenterol Date: 2009-01-27 Impact factor: 10.864
Authors: Roos E Pouw; Joep J Gondrie; Carine M Sondermeijer; Fiebo J ten Kate; Thomas M van Gulik; Kausilia K Krishnadath; Paul Fockens; Bas L Weusten; Jacques J Bergman Journal: J Gastrointest Surg Date: 2008-08-13 Impact factor: 3.452
Authors: R M Zagari; L Fuccio; M-A Wallander; S Johansson; R Fiocca; S Casanova; B Y Farahmand; C C Winchester; E Roda; F Bazzoli Journal: Gut Date: 2008-04-18 Impact factor: 23.059
Authors: Nicholas J Shaheen; Prateek Sharma; Bergein F Overholt; Herbert C Wolfsen; Richard E Sampliner; Kenneth K Wang; Joseph A Galanko; Mary P Bronner; John R Goldblum; Ana E Bennett; Blair A Jobe; Glenn M Eisen; M Brian Fennerty; John G Hunter; David E Fleischer; Virender K Sharma; Robert H Hawes; Brenda J Hoffman; Richard I Rothstein; Stuart R Gordon; Hiroshi Mashimo; Kenneth J Chang; V Raman Muthusamy; Steven A Edmundowicz; Stuart J Spechler; Ali A Siddiqui; Rhonda F Souza; Anthony Infantolino; Gary W Falk; Michael B Kimmey; Ryan D Madanick; Amitabh Chak; Charles J Lightdale Journal: N Engl J Med Date: 2009-05-28 Impact factor: 91.245
Authors: Jon C Gould; Mark R Wendling; Brant K Oeschlager; Sumeet K Mittal; Srinadh Komanduri; Kyle A Perry; Sean Cleary; Susan Galandiuk; Daniel J Scott; P Marco Fisichella; Nicholas J Shaheen; Kelly R Haisley; John G Hunter Journal: J Gastrointest Surg Date: 2017-02-27 Impact factor: 3.452
Authors: Sachin Wani; V Raman Muthusamy; Nicholas J Shaheen; Rena Yadlapati; Robert Wilson; Julian A Abrams; Jacques Bergman; Amitabh Chak; Kenneth Chang; Ananya Das; John Dumot; Steven A Edmundowicz; Glenn Eisen; Gary W Falk; M Brian Fennerty; Lauren Gerson; Gregory G Ginsberg; David Grande; Matt Hall; Ben Harnke; John Inadomi; Janusz Jankowski; Charles J Lightdale; Jitin Makker; Robert D Odze; Oliver Pech; Richard E Sampliner; Stuart Spechler; George Triadafilopoulos; Michael B Wallace; Kenneth Wang; Irving Waxman; Srinadh Komanduri Journal: Am J Gastroenterol Date: 2017-06-01 Impact factor: 10.864
Authors: Rebecca J Critchley-Thorne; Lucas C Duits; Jeffrey W Prichard; Jon M Davison; Blair A Jobe; Bruce B Campbell; Yi Zhang; Kathleen A Repa; Lia M Reese; Jinhong Li; David L Diehl; Nirag C Jhala; Gregory Ginsberg; Maureen DeMarshall; Tyler Foxwell; Ali H Zaidi; D Lansing Taylor; Anil K Rustgi; Jacques J G H M Bergman; Gary W Falk Journal: Cancer Epidemiol Biomarkers Prev Date: 2016-05-13 Impact factor: 4.254